This acquisition aims to strengthen the company’s presence in Austria by facilitating future development and investments in this market while ensuring the continued delivery of high-level products and services that Medacta customers have come to expect.

As part of the acquisition, Vivamed Chief Executive Officer and Co-founder Herbert Brandstätter will transition to Medacta Austria General Manager.

“Medacta’s growth, including expansion of the product portfolio in the areas of spine, shoulder and sports medicine, requires a substantial structural investment in the Austrian market,” said Alberto Siccardi, President and Founder of Medacta International.

 “We look forward to continuing our collaboration with Mr. Brandstätter, who will help us expand and strengthen our business in Austria.”

“After 15 years of close collaboration with Medacta International, Vivamed has become one of the main players in the Austrian joint replacement market,” said Herbert Brandstätter. “We have shared the pillars of Medacta’s mission and identity since the beginning of our partnership and are eager to join our talented teams.”

Medacta International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation.

Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS® system and total knee replacement with MyKnee® patient matched technology.

ow Forward also announced the closing of $1 million additional Series A financing, led by a group of individual investors.

This financing will support the further development of Flow Forward’s AFE System, a small, minimally invasive blood pump system designed for temporary use to rapidly dilate peripheral veins through flow-mediated vascular dilation prior to AVF surgery. Flow Forward previously raised $6 million in Series A funding, bringing the total funding raised to $7 million to date.

“The new funding provides Flow Forward with the resources to continue the development and testing of the AFE System,” said Franano.

“Currently, there are more than 2.3 million people worldwide on hemodialysis who depend on a vascular access site to receive this life-saving treatment. Unfortunately, most of these patients will, at some point, experience failure of their vascular access site, which can often lead to a cycle of painful, expensive repair and replacement procedures. Outflow vein and inflow artery diameter are critical factors in achieving and maintaining a functional AVF.

“Based on our bench and preclinical study results, we believe the AFE System could provide larger AVF inflow artery and outflow vein diameters, higher AVF flow rates, greater AVF maturation rates, faster AVF maturation, and increases in AVF primary and secondary patency rates.”